United States Deep Brain Stimulation In Parkinson’s Disease Market to Grow with a CAGR of 7.10% through 2029

Increasing prevalence of Parkinson's Disease, coupled with the effectiveness of DBS and ongoing technological advancements, is expected to drive the United States Deep Brain Stimulation In Parkinson’s Disease Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “United States Deep Brain Stimulation In Parkinson’s Disease Market – By Region, Competition, Forecast and Opportunities, 2029”, the United States Deep Brain Stimulation In Parkinson’s Disease Market stood at USD 522.01 million in 2023 and is anticipated to grow with a CAGR of 7.10% in the forecast period through 2029. This growth can be attributed to the expanding range of clinical indications for DBS. Initially used primarily for Parkinson's Disease, DBS applications now include other neurological disorders such as essential tremor, dystonia, and emerging areas like obsessive-compulsive disorder and epilepsy. The versatility of DBS systems in treating multiple conditions enhances their utilization, driving market expansion.

Additionally, the growing focus on patient-centered care will further boost the DBS market. Emphasizing patient-reported outcomes and quality of life measures, healthcare providers aim to improve overall well-being and satisfaction for patients undergoing DBS therapy. This trend aligns with the broader shift towards holistic healthcare approaches that prioritize patient experience and outcomes.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Deep Brain Stimulation In Parkinson’s Disease Market.”

The deep brain stimulation (DBS) devices market is significantly influenced by the rising prevalence of Parkinson's Disease (PD), the second most common neurodegenerative disorder after Alzheimer's Disease (AD). PD is caused by a combination of genetic factors, such as mutations in the alpha-synuclein gene, and environmental influences, including repeated head injuries, with age being a primary risk factor. According to the Parkinson's Foundation Prevalence Project, the number of individuals living with PD is projected to increase from 930,000 in 2020 to 1.2 million by 2030, surpassing the prevalence of conditions like muscular dystrophy, multiple sclerosis, and amyotrophic lateral sclerosis. In the U.S. alone, approximately 60,000 new PD diagnoses occur annually, driving the demand for DBS as a crucial therapeutic solution for managing PD symptoms.

The COVID-19 pandemic negatively impacted the market by affecting demand and production, disrupting supply chains, and placing financial burdens on businesses. Many neurological surgeries were postponed or canceled to prevent the spread of COVID-19, leading to a 55% decline in neurosurgical procedures in severely affected countries such as the U.S., Russia, India, Brazil, France, the U.K., Italy, and Spain. Emerging evidence also suggests that COVID-19 may contribute to neurological symptoms, including "brain fog." Manufacturers faced challenges in serving surgeons due to restricted hospital access, adversely affecting procedural volumes in 2020 and limiting market growth. However, the widespread adoption of tele-consultation for PD symptom management during the pandemic has supported market growth and is expected to continue influencing DBS adoption in the coming years.

Looking ahead, the market is anticipated to expand, driven primarily by increased sales volumes in the neuromodulation industry. Pricing competition in key markets like the U.S. has exerted pressure on DBS pricing, partially moderating growth. Additionally, many market players in the U.S. are strengthening their positions by launching more comprehensive and technologically advanced product portfolios, engaging in mergers and acquisitions, and expanding into new geographic markets.

The United States Deep Brain Stimulation In Parkinson’s Disease Market is segmented into product, regional distribution, and company.

Based on its product, In 2023, the dual-channel system dominated the market. High-frequency Deep Brain Stimulation (DBS) has emerged as a widely adopted method for managing severe movement disorders when medical treatments fall short. This procedure, recognized for its safety, bilaterality, and reversibility, involves inserting leads into targeted areas on both sides of the brain. The rising acceptance of dual-channel DBS for treating conditions such as Parkinson's disease, dystonia, Alzheimer's disease, and epilepsy is a key driver of growth in this segment. Looking ahead, the single-channel segment is expected to experience the most rapid growth. DBS devices, often referred to as brain pacemakers, have been used clinically for 25 years to treat Parkinson's disease. Single-channel DBS systems, which involve the implantation of a single lead, are favored by healthcare professionals for offering neurologists greater programming flexibility and achieving better motor outcomes.

Based on region, In 2023, the North-East region of the United States is expected to lead the Deep Brain Stimulation (DBS) market for Parkinson's Disease treatment due to several key factors. Firstly, the region is home to some of the country's most prestigious medical institutions and research centers, consistently developing groundbreaking innovations in neurology and DBS technology. These institutions attract top-tier talent and foster a culture of medical excellence, ensuring that cutting-edge treatments like DBS are widely available and adopted.

Moreover, the North-East has a dense elderly population, which is more susceptible to Parkinson's disease, creating a substantial patient base for DBS procedures. Additionally, the region boasts a strong healthcare infrastructure and a well-informed populace, leading to a high level of awareness and demand for advanced treatments like DBS. Collectively, these factors make the North-East a formidable force in shaping the future of the DBS market for Parkinson's Disease in the United States.

Major companies operating in United States Deep Brain Stimulation In Parkinson’s Disease Market are:

• Boston Scientific Corporation
• Abbott Laboratories Inc
• Medtronic PLC
• Functional Neuromodulation Inc
• Nuvectra Corp
• Aleva Neurotherapeutics SA

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The United States Deep Brain Stimulation in Parkinson’s Disease market is on the brink of transformation. With expanding clinical indications, miniaturized devices, personalized medicine, remote monitoring, closed-loop systems, and a heightened focus on patient-centered outcomes, the future of DBS therapy is promising. The key trends are set to revolutionize the landscape of DBS in the United States, offering new hope and improved quality of life for individuals living with Parkinson's Disease. As research and innovation continue to propel the field forward, patients and healthcare providers alike can look forward to a brighter future in the DBS market”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“United States Deep Brain Stimulation In Parkinson’s Disease Market By Product (Single-channel, Dual-channel), By Region, By Competition, Forecast & Opportunities, 2019-2029F”, has evaluated the future growth potential of United States Deep Brain Stimulation In Parkinson’s Disease Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Deep Brain Stimulation In Parkinson’s Disease Market.

Contact Us-

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

M: +13322586602                       

Email: [email protected]               

Website: www.techsciresearch.com